KRAS and lung carcinoma: We show that NMTis are effective as single agents against lung carcinomas with concurrent LKB1 and/or KEAP1 mutations in a KRAS-mutant background (KL/K)MUT and sensitize cells with these mutations to platinum-based chemotherapy.